Tanshinone IIA (Synonyms: 丹參酮IIA; Dan Shen ketone)

目錄號: HY-N0135 純度: 99.78%: FAQs
Data Sheet SDS COA 產(chǎn)品使用指南

摩爾計算器

Tanshinone IIA (Tan IIA) 是丹參根中的主要組合物之一。Tanshinone IIA 可以通過靶向 VEGF/VEGFR2 的蛋白激酶結(jié)構(gòu)域來抑制血管生成。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報，我們不為任何個人用途提供產(chǎn)品和服務(wù)

Tanshinone IIA Chemical Structure

CAS No. : 568-72-9

1. 客戶無需承擔(dān)相應(yīng)的運(yùn)輸費用。

2. 同一機(jī)構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機(jī)構(gòu)（單位）一年內(nèi)

可免費申領(lǐng)三個不同產(chǎn)品的試用裝。

3. 試用裝只面向終端客戶。

規(guī)格	價格	是否有貨
1 mg	￥185	In-stock
5 mg	￥370	In-stock
10 mg	￥600	In-stock
25 mg	￥1200	In-stock
50 mg	￥2100	In-stock
100 mg		詢價
200 mg		詢價

or 大包裝詢價

* Please select Quantity before adding items.

Customer Review

Other Forms of Tanshinone IIA:

Tanshinone IIA (Standard) 詢價

MCE 顧客使用本產(chǎn)品發(fā)表的 20 篇科研文獻(xiàn)

•Sci Total Environ. 2024 Sep 2:175879. [Abstract]
•J Transl Med. 2023 Jan 20;21(1):34. [Abstract]
•Phytother Res. 2022 Jul 8. [Abstract]
•Int J Mol Sci. 2024 Nov 21;25(23):12483. [Abstract]
•Life Sci Alliance. 2022 Nov 1;6(1):e202201667. [Abstract]
•Stem Cells Int. 04 Mar 2022.

•J Integr Med. 20 January 2022.
•Environ Toxicol. 2021 Oct 18. [Abstract]
•Cancer Cell Int. 2020 Aug 7;20:379. [Abstract]
•Eur J Pharmacol. 2020 Aug 5;880:173140. [Abstract]
•Chem-Biol Interact. 2020 Mar 1;319:109024. [Abstract]
•Acta Biochim Biophys Sin (Shanghai). 2024 Nov 1. [Abstract]
•Microb Pathog. 2024 Sep 21:106960. [Abstract]
•Exp Ther Med. June 16, 2022.
•Pharmacology. 2021 Jan 4;1-9. [Abstract]
•J Pharm Pharmacol. 2018 Oct;70(10):1369-1377. [Abstract]
•Mediators Inflamm. 2024 Mar 21.
•Research Square Preprint. 2023 Jun 29.
•Biomed Res Int. 2022 Sep 13;2022:3816258. [Abstract]
•Evid-Based Compl Alt. 15 Oct 2021.

Cell Viability Assay

: Tanshinone IIA purchased from MCE. Usage Cited in: J Transl Med. 2023 Jan 20;21(1):34. [Abstract]; Tanshinone IIA (Tan IIA; 24?h) significantly decreases the cell viability when concentration reaches to 50?μM in bEnd0.3 cells.

: Tanshinone IIA purchased from MCE. Usage Cited in: Eur J Pharmacol. 2020 Aug 5;880:173140. [Abstract]; Phospho-p65 (p-p65), p65, IL-1β, IL-6, TNF-α, and KLF4 expression in unligated, ligated and ligated + Tan IIA-treated carotid arteries is determined by Western blotting days 21 after carotid artery ligation.

: Tanshinone IIA purchased from MCE. Usage Cited in: J Pharm Pharmacol. 2018 Oct;70(10):1369-1377. [Abstract]; Tanshinone IIA induces TOV-21G apoptosis. Western blotting is performed with anti-Cleaved caspase 3 or anti-cleaved poly ADP-ribose polymerase (PARP) antibodies. Tubulin is loaded as the loading control.

Tanshinone IIA 相關(guān)產(chǎn)品

•相關(guān)化合物庫:

•同靶點產(chǎn)品:

•同靶點蛋白產(chǎn)品:

查看 VEGFR 亞型特異性產(chǎn)品:

查看所有亞型

VEGFR1/Flt-1 VEGFR2/KDR/Flk-1 VEGFR3/Flt-4

生物活性
純度 & 產(chǎn)品資料
參考文獻(xiàn)

生物活性

Tanshinone IIA (Tan IIA) is one of the main compositions in the root of Salvia miltiorrhiza Bunge. Tanshinone IIA may suppress angiogenesis by targeting the protein kinase domains of VEGF/VEGFR2.

IC₅₀ & Target

VEGF/VEGFR2^[1]

細(xì)胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
A549	IC₅₀	2.2 μM Compound: 2a	Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 34333396]
A549	IC₅₀	53.2 μM Compound: Tan-IIA	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 30398868]
A549	IC₅₀	6.68 μM Compound: 7; TSA	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by cell titer glo luminescent assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by cell titer glo luminescent assay	[PMID: 35640078]
AGS	IC₅₀	10 μM Compound: 7, tanshinone iia	Viability of human AGS cells under normoxic conditions after 24 hrs by MTT assay Viability of human AGS cells under normoxic conditions after 24 hrs by MTT assay	[PMID: 17583950]
AGS	IC₅₀	6.8 μM Compound: 7, tanshinone iia	Viability of human AGS cells under hypoxic conditions after 24 hrs by MTT assay Viability of human AGS cells under hypoxic conditions after 24 hrs by MTT assay	[PMID: 17583950]
AGS	IC₅₀	7.53 μM Compound: 7, tanshinone iia	Inhibition of HIF1 activation in human AGS cells assessed as inhibition of hypoxia-induced luciferase expression after 16 hrs by reporter assay Inhibition of HIF1 activation in human AGS cells assessed as inhibition of hypoxia-induced luciferase expression after 16 hrs by reporter assay	[PMID: 17583950]
BGC-823	IC₅₀	2.8 μM Compound: 10	Anticancer activity against human BGC-823 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay Anticancer activity against human BGC-823 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay	[PMID: 36332549]
CWR22R	IC₅₀	6.7 μM Compound: TS-IIA	Cytotoxicity against human 22Rv1 cells incubated for 72 hrs by MTT assay Cytotoxicity against human 22Rv1 cells incubated for 72 hrs by MTT assay	[PMID: 22175694]
HeLa	IC₅₀	193.2 μM Compound: Tan-IIA	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 30398868]
HeLa	IC₅₀	3.47 μM Compound: 2a	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 34333396]
Hep 3B2	IC₅₀	> 50 μM Compound: 7, tanshinone iia	Viability of human Hep3B cells under normoxic conditions after 24 hrs by MTT assay Viability of human Hep3B cells under normoxic conditions after 24 hrs by MTT assay	[PMID: 17583950]
Hep 3B2	IC₅₀	> 50 μM Compound: 7, tanshinone iia	Viability of human Hep3B cells under hypoxic conditions after 24 hrs by MTT assay Viability of human Hep3B cells under hypoxic conditions after 24 hrs by MTT assay	[PMID: 17583950]
Hep 3B2	IC₅₀	6.18 μM Compound: 7, tanshinone iia	Inhibition of HIF1 activation in human Hep3B cells assessed as inhibition of hypoxia-induced luciferase expression after 16 hrs by reporter assay Inhibition of HIF1 activation in human Hep3B cells assessed as inhibition of hypoxia-induced luciferase expression after 16 hrs by reporter assay	[PMID: 17583950]
HepG2	IC₅₀	23.85 μM Compound: TSA	Antiproliferative activity against human HepG2 cells by MTT assay Antiproliferative activity against human HepG2 cells by MTT assay	[PMID: 33601313]
HepG2	IC₅₀	4.91 μM Compound: 2a	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 34333396]
HepG2	IC₅₀	65.7 μM Compound: Tan-IIA	Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 30398868]
L02	IC₅₀	65.29 μM Compound: TSA	Antiproliferative activity against human L02 cells by MTT assay Antiproliferative activity against human L02 cells by MTT assay	[PMID: 33601313]
L02	IC₅₀	78.5 μM Compound: Tan-IIA	Antiproliferative activity against human L02 cells after 72 hrs by MTT assay Antiproliferative activity against human L02 cells after 72 hrs by MTT assay	[PMID: 30398868]
LNCaP	IC₅₀	0.5 μM Compound: TS-IIA	Cytotoxicity against human LNCAP cells incubated for 72 hrs by MTT assay Cytotoxicity against human LNCAP cells incubated for 72 hrs by MTT assay	[PMID: 22175694]
LNCaP C4-2B	IC₅₀	0.4 μM Compound: TS-IIA	Cytotoxicity against human C4-2B cells incubated for 72 hrs by MTT assay Cytotoxicity against human C4-2B cells incubated for 72 hrs by MTT assay	[PMID: 22175694]
MCF7	IC₅₀	> 5 μM Compound: 2a	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 34333396]
MCF7	EC₅₀	0.9 μM Compound: Tan II-A	Cytotoxicity against telomerase positive human MCF7 cells after 96 hrs by SRB assay Cytotoxicity against telomerase positive human MCF7 cells after 96 hrs by SRB assay	[PMID: 22044621]
MCF7	IC₅₀	7.7935 μM Compound: 2	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 33751939]
MDA-MB-231	IC₅₀	115.9 μM Compound: Tan-IIA	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 30398868]
MDA-MB-231	IC₅₀	7.695 μM Compound: 2	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 33751939]
MGC-803	IC₅₀	> 5 μM Compound: 2a	Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 34333396]
MIA PaCa-2	IC₅₀	1.9 μM Compound: 13	Cytotoxicity against human MIAPaCa2 cells after 24 hrs by MTT assay Cytotoxicity against human MIAPaCa2 cells after 24 hrs by MTT assay	[PMID: 21775156]
NCI-N87	IC₅₀	3.1 μM Compound: 10	Anticancer activity against human NCI-N87 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay Anticancer activity against human NCI-N87 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay	[PMID: 36332549]
PC-3	EC₅₀	1.2 μM Compound: Tan II-A	Cytotoxicity against telomerase positive human PC3 cells after 96 hrs by SRB assay Cytotoxicity against telomerase positive human PC3 cells after 96 hrs by SRB assay	[PMID: 22044621]
PC-3	IC₅₀	3.3 μM Compound: TS-IIA	Cytotoxicity against human PC3 cells incubated for 72 hrs by MTT assay Cytotoxicity against human PC3 cells incubated for 72 hrs by MTT assay	[PMID: 22175694]
SAOS-2	EC₅₀	> 20 μM Compound: Tan II-A	Cytotoxicity against telomerase negative human Saos2 cells after 96 hrs by SRB assay Cytotoxicity against telomerase negative human Saos2 cells after 96 hrs by SRB assay	[PMID: 22044621]
SGC-7901	IC₅₀	250 μM Compound: 10	Anticancer activity against human SGC-7901 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay Anticancer activity against human SGC-7901 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay	[PMID: 36332549]
U-937	IC₅₀	> 5 μM Compound: 2a	Antiproliferative activity against human U-937 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human U-937 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 34333396]

體外研究
(In Vitro)

Tanshinone IIA 的抗腫瘤作用包括抑制腫瘤細(xì)胞增殖、擾亂腫瘤細(xì)胞周期、促進(jìn)腫瘤細(xì)胞凋亡、抑制腫瘤細(xì)胞侵襲轉(zhuǎn)移等。Tanshinone IIA 對 A549 細(xì)胞具有抗增殖作用：24、48 和 72 h后 Tanshinone IIA 的 IC₅₀ 分別為 145.3、30.95 和 11.49 μM。CCK-8 測定用于評估分別用 Tanshinone IIA (2.5 -80 μM) 處理 24、48 和 72 小時的 A549 細(xì)胞的增殖活性。CCK-8 結(jié)果顯示 Tanshinone IIA 能以劑量和時間依賴性方式顯著抑制 A549 細(xì)胞增殖。藥物處理 48 小時后觀察到明顯的 A549 細(xì)胞凋亡和細(xì)胞生長抑制 (使用的濃度約為 IC₅₀ 值：Tanshinone IIA 31 μM 對 A549)。Western blotting 發(fā)現(xiàn)，在 A549 細(xì)胞中暴露于 Tanshinone IIA (31 μM) 48 小時后，與載體相比，兩個藥物處理組的 VEGF 和 VEGFR2 蛋白表達(dá)均下調(diào)^[1]。
Tanshinone IIA 是 Salvia miltiorrhiza 根中最豐富的成分之一，可保護(hù)大鼠心肌來源的 H9C2 細(xì)胞免于凋亡。用 Tanshinone IIA 處理 H9C2 細(xì)胞可通過下調(diào) PTEN (磷酸酶和張力蛋白同系物) 的表達(dá)來抑制血管緊張素 II 誘導(dǎo)的細(xì)胞凋亡，PTEN 是一種在細(xì)胞凋亡中起關(guān)鍵作用的腫瘤抑制因子。Tanshinone IIA 通過下調(diào)磷酸酶和張力蛋白同系物 (PTEN) 的表達(dá)來抑制血管緊張素 II (AngII) 誘導(dǎo)的細(xì)胞凋亡^[2]。
Tanshinone IIA 降低胃癌 AGS 細(xì)胞 EGFR 和 IGFR 蛋白表達(dá)，阻斷 PI3K/Akt/mTOR 通路^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

體內(nèi)研究
(In Vivo)

Tanshinone IIA (10 或 20 mg/kg；口服) 顯著逆轉(zhuǎn)東莨菪堿誘導(dǎo)的認(rèn)知障礙^[1]。
Tanshinone IIA (2、4、8 mg/kg；腹腔注射) 介導(dǎo)的保護(hù)作用對 STZ 誘導(dǎo)的糖尿病腎病的影響可能與通過減弱 PERK 信號活動減少內(nèi)質(zhì)網(wǎng)應(yīng)激有關(guān)^[2]。
Tanshinone IIA (3 和 12 mg/kg；ip) 顯著抑制異位子宮內(nèi)膜的生長^[3]。
Tanshinone IIA 在一些研究中與 Tanshinone IIA sulfonate sodium (HY-N1370) 被互相替代使用，但存在水溶性、化學(xué)結(jié)構(gòu)、藥理活性和藥代動力學(xué)差異。動物給藥時請配置固體分散劑，或選擇使用水溶性較好的磺酸鹽形式 Tanshinone IIA sulfonate sodium (HY-N1370)^[4]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male ICR mice (25–30 g)^[4]
Dosage:	10 or 20 mg/kg
Administration:	P.o.
Result:	Significantly reversed scopolamine-induced cognitive impairments.

Animal Model:	STZ-treated rats^[5]
Dosage:	2, 4, 8 mg/kg
Administration:	I.p.
Result:	Decreased the expression levels of transforming growth factor-beta1, TSP-1, Grp78 and CHOP and attenuated the increase in the protein levels of p-PERK, p-elf2α and ATF-4 from the renal tissues of diabetic rats.

Animal Model:	Female Sprague-Dawley rats (180 -200g)^[6]
Dosage:	3 and 12 mg/kg
Administration:	I.p.
Result:	Significantly inhibited the growth of ectopic endometrium.

分子量

294.34

Formula

C₁₉H₁₈O₃

CAS 號

568-72-9

性狀

固體

顏色

Pink to red

中文名稱

丹參酮 IIA

結(jié)構(gòu)分類

初始來源

運(yùn)輸條件

Room temperature in continental US; may vary elsewhere.

儲存方式

Powder	-20°C	3 years
	4°C	2 years

*該產(chǎn)品在溶液狀態(tài)不穩(wěn)定，建議您現(xiàn)用現(xiàn)配，即刻使用。

溶解性數(shù)據(jù)

細(xì)胞實驗：

DMSO 中的溶解度 : 1 mg/mL (3.40 mM; 超聲助溶 (<80°C); 吸濕的 DMSO 對產(chǎn)品的溶解度有顯著影響，請使用新開封的 DMSO)

配制儲備液

濃度溶劑體積質(zhì)量	1 mg	5 mg	10 mg

1 mM	3.3974 mL	16.9872 mL	33.9743 mL
5 mM	---	---	---
10 mM	---	---	---

查看完整儲備液配制表

* 請根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲備液；該產(chǎn)品在溶液狀態(tài)不穩(wěn)定，建議您現(xiàn)用現(xiàn)配，即刻使用。

摩爾計算器
稀釋計算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

濃度 _(start)

體積 _(start)

濃度 _(final)

體積 _(final)

動物實驗：

以下溶解方案，請直接配制工作液。建議現(xiàn)用現(xiàn)配，在短期內(nèi)盡快用完。以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶。

方案一

請依序添加每種溶劑： 0.5% CMC-Na/0.1% Tween-80 in Saline water
Solubility: 1 mg/mL (3.40 mM); 懸濁液; 超聲助溶

動物溶解方案計算器

請輸入動物實驗的基本信息：

給藥劑量

mg/kg

動物的平均體重

每只動物的給藥體積

μL

動物數(shù)量

只

由于實驗過程有損耗，建議您多配一只動物的量

計算結(jié)果

工作液所需濃度 : mg/mL

純度 & 產(chǎn)品資料

純度: 99.78%

選擇批次：

Data Sheet (662 KB) SDS (393 KB)

COA (299 KB) HNMR (138 KB) RP-HPLC (221 KB) LCMS (95 KB)

產(chǎn)品使用指南 (1538 KB)

參考文獻(xiàn)

[1]. Xie J, et al. The antitumor effect of tanshinone IIA on anti-proliferation and decreasing VEGF/VEGFR2 expression on the human non-small cell lung cancer A549 cell line. Acta Pharm Sin B. 2015 Nov;5(6):554-63. [Content Brief]

[2]. Zhang Z, et al. Tanshinone IIA inhibits apoptosis in the myocardium by inducing microRNA-152-3p expression and thereby downregulating PTEN. Am J Transl Res. 2016 Jul 15;8(7):3124-32. [Content Brief]

[3]. Su CC, et al. Tanshinone IIA decreases the protein expression of EGFR, and IGFR blocking the PI3K/Akt/mTOR pathway in gastric carcinoma AGS cells both in vitro and in vivo. Oncol Rep. 2016 Aug;36(2):1173-9. [Content Brief]

[4]. Zhongyan Zhou, et al. Sodium tanshinone IIA sulfonate: a review of pharmacological activity and pharmacokinetics. Biomedicine & Pharmacotherapy 118 (2019): 109362. [Content Brief]

Tanshinone IIA 相關(guān)分類

完整儲備液配制表

可選溶劑	濃度溶劑體積質(zhì)量	1 mg	5 mg	10 mg	25 mg

DMSO

1 mM

3.3974 mL

16.9872 mL

33.9743 mL

84.9358 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Tanshinone IIA568-72-9Dan Shen ketone丹參酮 IIAVEGFRVascular endothelial growth factor receptorInhibitorinhibitorinhibit

產(chǎn)品名稱：			* 需求量：
* 客戶姓名：			* Email：
* 電話：			* 公司或機(jī)構(gòu)名稱：
留言給我們：

產(chǎn)品名稱：			* Lot #：
* 客戶姓名：			* Email：
電話：			* 部門：
* 公司或機(jī)構(gòu)名稱：
留言給我們：

MedChemExpress (MCE) 只為有資質(zhì)的科研機(jī)構(gòu)、醫(yī)藥企業(yè)基于科學(xué)研究或藥證申報的用途提供醫(yī)藥研發(fā)服務(wù)，不為任何個人或者非科研性質(zhì)的、非用于藥證申報使用等其他用途提供服務(wù)。	站點地圖隱私聲明
滬ICP備15051369號-4 上海工商滬公網(wǎng)安備31011502019417 滬(浦)應(yīng)急管危經(jīng)許[2021]201709(QFYS) 營業(yè)執(zhí)照（三證合一）
Copyright ? 2013-2025 MedChemExpress. All Rights Reserved.

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Tanshinone IIA (Synonyms: 丹參酮IIA; Dan Shen ketone)

Customer Review

Other Forms of Tanshinone IIA:

MCE 顧客使用本產(chǎn)品發(fā)表的 20 篇科研文獻(xiàn)

Tanshinone IIA 相關(guān)產(chǎn)品

•相關(guān)化合物庫:

•同靶點產(chǎn)品:

•同靶點蛋白產(chǎn)品:

查看 VEGFR 亞型特異性產(chǎn)品:

生物活性

純度 & 產(chǎn)品資料

參考文獻(xiàn)

摩爾計算器

稀釋計算器

Tanshinone IIA 相關(guān)分類

完整儲備液配制表

Keywords:

您最近查看的產(chǎn)品:

熱門區(qū)域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
郵箱 *

Sorry, but the email address you supplied was invalid.

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Tanshinone IIA (Synonyms: 丹參酮IIA; Dan Shen ketone)

Customer Review

Other Forms of Tanshinone IIA:

Tanshinone IIA 相關(guān)抗體

MCE 顧客使用本產(chǎn)品發(fā)表的 20 篇科研文獻(xiàn)

Tanshinone IIA 相關(guān)產(chǎn)品

•相關(guān)化合物庫:

•同靶點產(chǎn)品:

•同靶點蛋白產(chǎn)品:

查看 VEGFR 亞型特異性產(chǎn)品:

生物活性

純度 & 產(chǎn)品資料

參考文獻(xiàn)

Tanshinone IIA 相關(guān)抗體:

摩爾計算器

稀釋計算器

Tanshinone IIA 相關(guān)分類

完整儲備液配制表

Keywords:

您最近查看的產(chǎn)品:

Request for HNMR Report

Request for HNMR Report

熱門區(qū)域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z